Rimidi, Inc. (formerly known as Rimidi Diabetes, Inc.), an Atlanta, GA-based digital health company that provides software and clinical analytics for chronic disease management, raised $6.575m in Series A-1 financing.
Backers included a strategic investment by Eli Lilly and Company, an investment from Turner Investments, and participation from existing investors Cox Enterprises, Village Capital, The Jump Fund, and JAMB Global. Both Lilly and Turner will take board seats.
The company intends to use the funds to accelerate growth and market penetration.
Led by CEO Josh Claman, Rimidi provides a platform that allows clinicians to personalize care for individuals by leveraging both patient generated data, clinical information, and practice guidelines. The solution, which enables clinicians to identify individuals who may benefit from specific therapeutic approaches, integrates with electronic medical records systems, providing a workflow experience for clinicians at the point of care.
FinSMEs
10/07/2018